376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated surviva... von Modi, S., Jacot, W., Iwata, H., Park, Y.H., Losada, M.J. Vidal, Li, W., Tsurutani, J., Zaman, K., Ueno, N.T., Prat, A., Papazisis, K., Rugo, H.S., Harbeck, N., Im, S-A., De Laurentiis, M., Orbegoso, C.M.A., Yung, L., Cheng, F-C., Cheng, Y., Cameron, D.A.

Volltext

192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-lo... von Cameron, D.A.A., Jacot, W., Yamashita, T., Losada, M.J. Vidal, Schmid, P., Lee, K.S., De Laurentiis, M., Zagouri, F., Ueno, N.T., Prat, A., Harbeck, N., Yerushalmi, R., Lu, Y-S., Gombos, A., Orbegoso, C.M.A., Cheng, F-C., Yung, L., Rajagopalan, R., Tsurutani, J., Modi, S.

Volltext

185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety a... von Rugo, H.S., Jacot, W., Tokunaga, E., Sohn, J., Cardoso, F., Xu, B., Losada, M.J. Vidal, Gil, M.J., Ueno, N.T., Prat, A., Moore, H., Hasler-Strub, U., Cameron, D.A.A., Lindman, H., Mezei, K., Rajagopalan, R., Orbegoso, C.M.A., Cheng, F-C., Puri, A., Modi, S.

Volltext

Olaparib maintenance treatment, the Royal Marsden experience von Orbegoso Aguilar, C.M.A., Dumas, L., Davies, E., Gore, M., George, A., Banerjee, S.

Volltext

MMR deficiency(d) in an unselected cohort of endometrial cancer (EC) patients, the Royal Marsden experience von Orbegoso Aguilar, C.M.A., Vroobel, K., Attygalle, A., Lalondrelle, S., Taylor, A., Nobbenhuis, M., Banerjee, S., George, A.

Volltext

Prevalence and clinical implications of mismatch repair (MMR) deficiency in unselected endometrial cancer (EC) patients von Orbegoso Aguilar, C.M.A., Vroobel, K., Lalondrelle, S., Taylor, A., Nobbenhuis, M., Attygalle, A., Banerjee, S., George, A.

Volltext